User profiles for Zachary A. Cooper
 | Zachary A CooperAstraZeneca Verified email at astrazeneca.com Cited by 22787 |
The human tumor microbiome is composed of tumor type–specific intracellular bacteria
Bacteria were first detected in human tumors more than 100 years ago, but the characterization
of the tumor microbiome has remained challenging because of its low biomass. We …
of the tumor microbiome has remained challenging because of its low biomass. We …
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Drug resistance presents a challenge to the treatment of cancer patients. Many studies have
focused on cell-autonomous mechanisms of drug resistance. By contrast, we proposed that …
focused on cell-autonomous mechanisms of drug resistance. By contrast, we proposed that …
Loss of PTEN promotes resistance to T cell–mediated immunotherapy
T cell–mediated immunotherapies are promising cancer treatments. However, most patients
still fail to respond to these therapies. The molecular determinants of immune resistance are …
still fail to respond to these therapies. The molecular determinants of immune resistance are …
[PDF][PDF] Defining T cell states associated with response to checkpoint immunotherapy in melanoma
Treatment of cancer has been revolutionized by immune checkpoint blockade therapies.
Despite the high rate of response in advanced melanoma, the majority of patients succumb to …
Despite the high rate of response in advanced melanoma, the majority of patients succumb to …
Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine
Growing evidence suggests that microbes can influence the efficacy of cancer therapies. By
studying colon cancer models, we found that bacteria can metabolize the chemotherapeutic …
studying colon cancer models, we found that bacteria can metabolize the chemotherapeutic …
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma
Purpose: To evaluate the effects of BRAF inhibition on the tumor microenvironment in patients
with metastatic melanoma. Experimental Design: Thirty-five biopsies were collected from …
with metastatic melanoma. Experimental Design: Thirty-five biopsies were collected from …
Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade
Immune checkpoint blockade represents a major breakthrough in cancer therapy; however,
responses are not universal. Genomic and immune features in pretreatment tumor biopsies …
responses are not universal. Genomic and immune features in pretreatment tumor biopsies …
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade
Abstract Treatment with combined immune checkpoint blockade (CICB) targeting CTLA-4 and
PD-1 is associated with clinical benefit across tumor types, but also a high rate of immune-…
PD-1 is associated with clinical benefit across tumor types, but also a high rate of immune-…
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance
Immune checkpoint blockade produces clinical benefit in many patients. However, better
biomarkers of response are still needed, and mechanisms of resistance remain incompletely …
biomarkers of response are still needed, and mechanisms of resistance remain incompletely …
A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors
…, CM Johannessen, O Abudayyeh, JW Kim, ZA Cooper… - Cancer discovery, 2014 - AACR
Most melanomas harbor oncogenic BRAF V600 mutations, which constitutively activate the
MAPK pathway. Although MAPK pathway inhibitors show clinical benefit in BRAF V600 -…
MAPK pathway. Although MAPK pathway inhibitors show clinical benefit in BRAF V600 -…
